Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine. Themis Measles Vector Technology Central to Action Plan

Vienna (Austria), 13 December 2016

Leading European research groups pool their expertise for the fast development of an effective and affordable vaccine against the Zika virus. Supported with very substantial funding by the EU, the ZIKAVAX consortium consists of Themis,the European Vaccine Initiative, Institut Pasteur and the Commissariat à l'énergie atomique et aux énergies alternatives. Pivotal to the joint development initiative is Themis' propietary technology platform based on a well-established measles vaccine vector.

A safe, effective and affordable vaccine for the prevention of Zika virus infections is the aim of the newly established ZIKAVAX consortium. To this end, the consortium received 5 M EUR funding from the EU's Horizon 2020 program which supports combating this emerging infectious disease that rapidly spreads to previously unaffected regions of the world. Partners in the consortium are the nonprofit product development partnership European Vaccine Initiative (ZIKAVAX coordinator), the world renowned Institut Pasteur in Paris, the successful vaccine developer Themis from Vienna, Austria and the Commissariat à l'énergie atomique et aux énergies alternatives (CEA), a french public government-funded research organization.

At the heart of the joint effort will be the Themaxyn® platform of Themis, a vector technology with a preclinical and clinical track record of adaptability and effectiveness for the development of vaccines. This successful technology uses a standard measles virus vaccine as a vector, developed at Institut Pasteur in Paris. It has proven its excellent safety profile and clear advantages in terms of a validated, low-cost production process in hundreds of millions of people globally who have received measle vaccinations. Dr. Erich Tauber, CEO and co-founder of Themis comments: "The recently phase 1 clinical trial results of our lead product, a Chikungunya vaccine, which is now tested in a phase 2 trial, have proven the suitability of the vector for other indications and we will now pursue the adaption of the technology for developing a Zika vaccine. The exceptional expertise combined in ZIKAVAX will guarantee quick progress and we are happy to be part of this consortium."

"Developing an effective Zika vaccine has become a global health priority for preventing the further spread of the virus. We are convinced that the use of the measles vaccine delivery platform, one of the safest and most efficacious vaccines available to date, will allow for a rapid and cost-effective development of a Zika vaccine", says Dr. Odile Leroy, Executive Director of the European Vaccine Initiative and coordinator of the ZIKAVAX project.

The work of the ZIKAVAX consortium will compliment Themis' internal Zika R&D project, with the common goal of developing a Zika vaccine rapidly. Themis has tested a number of candidate vaccines in animal models, initiated a toxicity study and established GMP manufacturing with the goal to start phase 1 trials early next year. This expertise and progress is very welcome by the consortium and has additionally been acknowledged by the United Kingdom's innovation agency, Innovate UK, with a 1 M GBP grant to Themis for the development of a Zika vaccine.

Quick Facts about ZIKAVAX:

Start Date: 1 October 2016

End Date: 30 September 2020

Coordinator: Odile LEROY, European Vaccine Initiative

Project Funding: EU H2020


Dr. Odile Leroy

European Vaccine Initiative (EVI)

Email: [YjY0dGFnOmNvbnRhY3QudXNAZXV2YWNjaW5lLmV1]

Phone: +49 / 6221 / 565974


Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline


Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting


Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK


Chikungunya-Fever: Themis Bioscience Starts Phase II Clinical Study in Endemic Area


NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine


Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine


Themis Bioscience Successfully Closes 10 M EUR Financing Round


Zika Vaccine Development Receives Big Boost by Innovate UK


Interview W24/Zika


New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority.


New Horizons For Measles-Based Vaccines And Therapies


Two renowned Vaccine Experts Joining Themis Bioscience GmbH


Themis Bioscience’s Raises up to EUR 10 Million in Series B New Board to drive partnerships and commercialization of product pipeline